Want to see NZ:TRU full AI Analyst Report?
Top Page
TruScreen Group Ltd.
(TRU)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.01
Action:N/A
Date:10/05/26
The score is primarily held back by weak financial performance—especially the sharp gross margin collapse, large ongoing losses, and persistent negative free cash flow that increases funding risk. Technicals also lean bearish with price below all major moving averages and negative MACD. Valuation provides limited support because the negative P/E reflects losses and dividend yield data is unavailable.
Positive Factors
Revenue rebound and commercial growth
The sharp FY2026 revenue rebound indicates improving commercial traction and broader customer adoption of TruScreen’s screening system. If the company can sustain this momentum across its expanding markets, higher scale could support stronger operating leverage and recurring consumables revenue over time.
Negative Factors
Severe gross-margin and profitability deterioration
The collapse in gross margin shows that recent revenue growth has not translated into a sustainable earnings model. Continued operating and net losses constrain internally funded investment, weaken the capital base, and make future scaling dependent on a substantial improvement in product economics.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound and commercial growth
The sharp FY2026 revenue rebound indicates improving commercial traction and broader customer adoption of TruScreen’s screening system. If the company can sustain this momentum across its expanding markets, higher scale could support stronger operating leverage and recurring consumables revenue over time.
Read all positive factors
TruScreen Group Ltd. (TRU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.62M
Dividend YieldN/A
Average Volume (3M)469.07K
Price to Earnings (P/E)―
Beta (1Y)-0.08
Revenue Growth42.20%
EPS Growth23.68%
CountryNZ
Employees6
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,047,718,900
10 Day Avg. Volume406,042
30 Day Avg. Volume469,072
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)4.89
Price to Sales (P/S)5.20
P/FCF Ratio-5.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
TruScreen Group Ltd. Business Overview & Revenue Model
Company Description
TruScreen Group Limited, alongside its subsidiaries, focuses on the development, manufacturing, and global distribution of advanced systems for cancer detection. Their commercial reach extends across various international territories, including Me...
How the Company Makes Money
TruScreen Group Ltd. makes money primarily by selling and/or supplying its TruScreen cervical screening systems to healthcare providers and channel partners, and by generating recurring revenue from related disposable components and consumables us...
TruScreen Group Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
57
Neutral
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.43M | 1.71M | 2.60M | 1.66M | 1.68M |
| Gross Profit | 25.48K | 515.22K | 1.16M | 459.99K | 522.74K |
| EBITDA | -2.64M | -2.12M | -2.55M | -2.78M | -7.94M |
| Net Income | -2.25M | -2.24M | -2.05M | -2.40M | -7.89M |
Balance Sheet | |||||
| Total Assets | 3.75M | 1.85M | 4.03M | 3.47M | 4.39M |
| Cash, Cash Equivalents and Short-Term Investments | 1.46M | 365.47K | 2.73M | 2.16M | 2.80M |
| Total Debt | 200.69K | 317.37K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.16M | 839.98K | 798.45K | 928.16K | 991.89K |
| Stockholders Equity | 2.59M | 1.01M | 3.23M | 2.54M | 3.40M |
Cash Flow | |||||
| Free Cash Flow | -2.47M | -2.29M | -2.03M | -2.24M | -2.53M |
| Operating Cash Flow | -2.47M | -2.29M | -2.03M | -2.19M | -2.53M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -49.70K | -2.66K |
| Financing Cash Flow | 3.49M | -84.40K | 2.58M | 1.55M | 0.00 |
TruScreen Group Ltd. Technical Analysis
Negative
―
Price Trends
0.02
Negative
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Positive
40.34
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:TRU, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 0.01, equal to the 50-day MA of 0.02, and equal to the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.34 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NZ:TRU.
TruScreen Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $27.05B | 58.10 | 22.84% | 1.63% | 15.59% | 23.94% | |
60 Neutral | $3.92B | 14.35 | 7.99% | 6.57% | 16.36% | 5.52% | |
54 Neutral | $458.30M | 30.91 | 14.07% | 0.67% | 22.44% | 23.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $514.20M | 3,525.00 | 0.02% | 4.16% | 2.52% | -99.52% | |
44 Neutral | $13.62M | -3.87 | -75.57% | ― | 42.20% | 23.68% | |
42 Neutral | $310.47M | -6.27 | -190.54% | ― | -47.36% | -3.79% |
* Healthcare Sector Average
NZ:TRU
TruScreen Group Ltd.
0.01
>-0.01
-29.41%
NZ:EBO
EBOS Group Limited
18.50
-9.44
-33.78%
NZ:FPH
Fisher & Paykel Healthcare Corporation Limited
46.57
9.52
25.70%
NZ:OCA
Oceania Healthcare
0.70
>-0.01
-0.71%
NZ:PEB
Pacific Edge Limited
0.24
0.04
23.08%
NZ:AFT
AFT Pharmaceuticals Ltd.
4.30
1.51
54.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.